Analysts expect Polaryx Therapeutics, Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Polaryx Therapeutics, Inc. to report earnings per share of -0.04 for Q2 26, against a range of -0.04 to -0.04. The most recent reported quarter, Q1 26, came in at -0.05, a 150.0% miss against the -0.02 consensus.
| Metric | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.03 | -0.13 | -0.05 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | - | -0.02 | -0.04 | -0.05 | -0.06 | -0.07 | -0.07 | -0.07 | -0.08 | -0.07 | |||||||||||
| Low Estimate | - | - | -0.02 | -0.04 | -0.05 | -0.06 | -0.07 | -0.07 | -0.07 | -0.08 | -0.09 | |||||||||||
| Consensus Estimate | - | - | -0.02 | -0.04 | -0.05 | -0.06 | -0.07 | -0.07 | -0.07 | -0.08 | -0.08 |